NPPA Trade Margin Cap on 137 Cancer Drugs Targets ₹3,540 Crore in Annual Savings
Revised prices took effect on November 9, 2026, with the government reporting reductions of more than 50% for 679 brands.
The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins on 137 identified anti-cancer drugs, with the government estimating annual consumer savings of ₹3,540.38 crore.
The NPPA trade margin cap was notified on October 17, 2026, and revised maximum retail prices became effective on November 9, 2026. The measure aims to reduce excessive margins in the distribution and retail supply chain and improve access to cancer medicines.
According to the government’s November 9 announcement, 85 pharmaceutical companies had reported revised prices for 1,364 anti-cancer formulations covering 121 drugs as of November 8.
The policy’s coverage of 137 drugs and the reporting snapshot of 121 drugs represent different measures: the first describes the notified list, while the second reflects the medicines covered by price submissions at that date.
NPPA Trade Margin Cap: Key Details
| Policy component | Details |
|---|---|
| Drugs covered by the intervention | 137 identified non-scheduled anti-cancer drugs |
| Trade-margin ceiling | 30% of the pre-tax retail price |
| Notification date | October 17, 2026 |
| Revised prices effective from | November 9, 2026 |
| Companies reporting revised prices | 85, as of November 8 |
| Formulations covered by reported revisions | 1,364, covering 121 drugs |
| Brands reporting reductions above 50% | 679 |
| Highest reported MRP reduction | 96.45% |
| Estimated annual consumer savings | ₹3,540.38 crore |
What the 30% Trade-Margin Limit Means
A trade margin is the difference between the price charged to a distributor or stockist and the retail price paid by the consumer, excluding applicable tax.
Large margins between these stages can substantially increase the amount patients pay for medicines.
Under the government’s explanation of the revised framework, prices are calculated using the average distributor price from March 2026. The trade-margin component is limited to 30% of the pre-tax retail price, with applicable GST added separately.
The resulting reduction varies according to a product’s previous retail price and its distributor price. The 30% figure therefore describes the permitted margin; individual medicines can experience different percentage reductions in MRP.
Why 137 Drugs Can Cover More Than 1,300 Formulations
A drug may be available through several brands, strengths and dosage forms. This means a list of 137 drugs can cover a much larger number of marketed formulations.
The November 9 government announcement reported revised MRPs for 1,364 formulations across 121 drugs, based on submissions received by November 8.
An earlier government update also explained that some medicines included in the notified list had yet to be launched in India. The trade-margin framework would apply to those medicines when they entered the market.
These distinctions help explain why the number of notified drugs differs from the number covered by companies’ reported price revisions.
Several Brands Report Substantial Price Reductions
The government said 679 brands reported MRP reductions exceeding 50%, while the largest reported reduction reached 96.45%.
These figures show substantial reductions for many products, although the benefit varies by medicine and brand.
A November 7 government release published the following illustrative revised prices:
| Brand and formulation | Previous listed MRP | Revised listed MRP |
|---|---|---|
| Bryxta — bevacizumab 100 mg injection | ₹25,995.00 | ₹3,318.00 |
| Pegex — pegfilgrastim 6 mg injection | ₹6,270.45 | ₹1,527.78 |
| Azacytin — azacitidine 100 mg injection | ₹6,337.00 | ₹1,495.04 |
These are individual entries from the government’s published list. Patients can verify the applicable price against the exact brand, strength and pack supplied.
How the ₹3,540 Crore Savings Estimate Was Calculated
The government’s background explanation describes annual savings as the difference between previous and revised prices, applied to sales volumes recorded from April 2025 to March 2026.
The ₹3,540.38 crore figure is therefore an estimated annual consumer benefit, based on historical sales and reported price changes.
Actual savings for an individual patient will depend on the prescribed medicine, its brand and strength, the quantity purchased and the price previously paid.
The estimate concerns spending on covered medicines. Other components of cancer care, including consultations, diagnostic tests, procedures and hospital services, have separate costs.
Which Medicines Fall Within the Policy?
The intervention covers identified non-scheduled anti-cancer drugs, including patented medicines. Non-scheduled medicines are those outside the First Schedule of the Drugs (Prices Control) Order, 2013.
Medicines highlighted in the government’s announcement include pembrolizumab, durvalumab, osimertinib, bevacizumab, denosumab and pegfilgrastim.
The list was recommended by an expert committee under the Directorate General of Health Services. NPPA introduced the measure using its public-interest powers under Paragraph 19 of the pricing order.
The initiative expands an earlier trade-margin rationalisation exercise introduced in 2019 for 42 anti-cancer drugs.
Hospitals and Pharmacies Must Apply the Revised Prices
The government has stated that chemists and hospital pharmacies cannot charge above the applicable revised MRP.
Manufacturers, retailers and hospitals are required to communicate or display updated prices, while State Drug Controllers are responsible for monitoring compliance. Manufacturers are also required to maintain supply in accordance with the notification’s requirements.
Patients and caregivers can check prices through the Pharma Sahi Daam app and NPPA’s published price information. Pricing complaints can be submitted through Pharma Jan Samadhan or the NPPA helpline, 1800-111-255.
With revised prices now effective, implementation at retail and hospital pharmacies will determine how consistently the announced reductions reach patients.
For more insights navigate: PressPire | Stories That Shape the Future
Read previous article here : odisha-pumped-storage-project-4708-crore/
Follow PressPire on Facebook | Instagram | LinkedIn | YouTube
PressPire | Stories That Shape the Future